「dysfunction」を含む例文一覧(260)

＜前へ 1 2 3 4 5 6
  • A compound of Formula I or a pharmaceutically acceptable salt thereof is used for treating or preventing a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, and early-onset essential hypertension, or the like.
    式Ｉの化合物又は薬学的に許容されるその塩を、痛風、高尿酸血症、高尿酸血症と診断することが慣例的に正しいとされるレベルに満たない尿酸値上昇、腎機能不全、腎臓結石、心血管疾患、心血管疾患発症リスク、腫瘍溶解症候群及び認知障害及び早発性本態性高血圧症などさまざまな状態を治療又は予防するために使用する。 - 特許庁
  • The therapeutic agent which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis, and as a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated, for example, the therapeutic agent for tuberculosis comprises a poly(lactic acid/glycolic acid) copolymer.
    マクロファージの貪食機能を活性化しこれを利用して、マクロファージに積極的に貪食されることでマクロファージに効率的に取り込ませ、これにより、機能異常となったマクロファージを正常化する、病原体感染マクロファージを殺滅する、又は、病原体感染マクロファージ内の病原体を殺滅する治療薬であって、例えば（ポリ（乳酸／グリコール酸）共重合体）を含み、結核に対する治療薬。 - 特許庁
  • To provide a method of detecting a cognitive disorder including light cognitive disfunction disorder and an Alzheimer's disease using proteins different in present amount and the partial peptides of the same in a non-cognitive dysfunction examinee and a cognitive disorder patient as well as a biomarker, and at the same time to provide a method of detecting a mental disorder other than the cognitive disorder, and a biomarker therefor.
    非認知機能障害被験者と認知機能障害疾患患者において存在量が異なるタンパク質およびその部分ペプチドを用いて軽度認知機能障害およびアルツハイマー病を含む認知機能障害疾患を検出する方法ならびに該タンパク質および該部分ペプチドからなる軽度認知機能障害およびアルツハイマー病を含む認知機能障害疾患検出のためのバイオマーカーの提供。 - 特許庁
  • (2) When an application set forth in the preceding paragraph is made, the prefectural government shall decide whether to pay Institutional Benefits for Disabled Children, by taking into consideration the type and level of the dysfunction of the disabled child pertaining to said application, the state of a caretaker of said disabled child, the state of receipt of Institutional Benefits for Disabled Children by the guardian of said disabled child, and other matters specified by an Ordinance of the Ministry of Health, Labour and Welfare.
    ２　都道府県は、前項の申請が行われたときは、当該申請に係る障害児の障害の種類及び程度、当該障害児の介護を行う者の状況、当該障害児の保護者の障害児施設給付費の受給の状況その他の厚生労働省令で定める事項を勘案して、障害児施設給付費の支給の要否を決定するものとする。 - 日本法令外国語訳データベースシステム
  • To provide an estrogen-like activator having therapeutic/prophylactic effects on diseases/symptoms caused by lowering of an estrogen content in a human body, e.g. female premenstrual syndrome and/or coronary artery diseases, osteoporosis, lipid abnormalities, symptoms of menopausal and/or postmenopausal disorders including climacteric disorders, sexual dysfunction, etc., and male prostatic cancer, prostatic hypertrophy, alopecia, etc.
    ヒトの体内のエストロゲン含量が低下することにより引き起こされる疾患・症状、例えば、女性の月経前症候群及び／又は心冠疾患、骨粗鬆症、脂質代謝異常、更年期障害、性機能低下等を含む閉経期及び／又は閉経後障害の症状、及び男性の前立腺癌、前立腺肥大症、脱毛症等にたいして治療・予防効果を有するエストロゲン様活性剤を提供する。 - 特許庁
  • To provide a PDE V inhibitor having beneficial therapeutic properties, useful pharmacological properties, and good metabolic stability and to provide a PDE V inhibitor which is still more potent and selective than other PDE inhibitors and is effective to treat various physiological conditions and diseases in which PDE V plays a certain role (especially to treat erectile dysfunction with minimized side effects).
    有益な治療特性、有用な薬理学的特性および良好な代謝安定性を有するＰＤＥ Ｖ阻害剤を提供すること、さらに、他の種類のＰＤＥ阻害剤よりも非常に強力かつ選択的なＰＤＥ Ｖ阻害剤であって、ＰＤＥ Ｖが一定の役割を果たす種々の生理症状および疾患を治療する（特に、副作用を最小にして勃起不全を治療する）のに有効なＰＤＥ Ｖ阻害剤を提供すること。 - 特許庁
  • To provide compositions and methods for therapeutic or prophylactic treatment of myocardial fibrosis or associated conditions (hypertension, diabetes, myocarditis, ischemic heart disease, left ventricular hypertrophy, cardiomyopathy, left ventricular dysfunction, congestive heart failure, therapy by medicines such as daunorubicin and others used in cancer chemotherapy, hereditary predispositions, Conn's syndrome, other conditions such as phaeochromocytoma, high salt diet, and the like).
    心筋線維症または関連症状（高血圧、糖尿病、心筋炎、虚血性心疾患、左室肥大、弛緩性機能障害、心筋炎、心筋症、左室機能不全、うっ血性心不全、癌化学療法で使われるダウノルビシンおよびその他といった薬剤による治療、遺伝的素因、コン症候群および褐色細胞腫といったその他の症状、高塩分食事等）の治療的または予防的な処置のための組成物および方法の提供。 - 特許庁
  • The compound represented by formula (I) of the present invention exhibits an excellent β3-adrenoceptor stimulating effect and relaxes bladder detrusor muscle as well as increases the volume of bladder. Therefore, compound (I) of the present invention can be used for the treatment of dysuria such as pollakiuria, urinary incontinence in the case of nervous pollakiuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic or acute cystitis, chronic or acute prostatitis, prostatic hypertrophy and the like, idiopathic pollakiuria, idiopathic urinary incontinence and the like.
    本発明の式（Ｉ）で表される化合物は、優れたβ３－アドレナリン受容体刺激作用を示し、膀胱排尿筋を弛緩させ、膀胱容量を増加させる作用を有するので排尿障害（例えば、神経性頻尿症、神経因性膀胱機能障害、夜間頻尿症、不安定膀胱、膀胱痙攣、慢性または急性膀胱炎、慢性または急性前立腺炎、前立腺肥大などにおける頻尿症、尿失禁、あるいは特発性頻尿症、尿失禁など）の治療に用いることができる。 - 特許庁
  • Article 24-22 A payment of Institutional Medical Expenses for Disabled Children shall not be made within the limit equivalent to the amount that a recipient can receive according to the state of the referenced dysfunction as prescribed in the subsequent sentence. When the recipient can receive dependent medical treatment expenses pursuant to the Health Insurance Act or other benefits pursuant to relevant laws and regulations and such expenses or benefits are specified by a Cabinet Order and fall under the payment of Institutional Medical Expenses for Disabled Children, the limit specified by a Cabinet Order shall apply as the limit referred to in the preceding sentence, and when any benefit other than those specified by said Cabinet Order that falls under the payment of Institutional Medical Expenses for Disabled Children is paid and borne by the national government or local government, the amount so paid shall apply as the limit referred to in the preceding sentence.
    第二十四条の二十二　障害児施設医療費の支給は、当該障害の状態につき、健康保険法の規定による家族療養費その他の法令に基づく給付であつて政令で定めるもののうち障害児施設医療費の支給に相当するものを受けることができるときは政令で定める限度において、当該政令で定める給付以外の給付であつて国又は地方公共団体の負担において障害児施設医療費の支給に相当するものが行われたときはその限度において、行わない。 - 日本法令外国語訳データベースシステム
  • (2) For the time being, with regard to a person of 18 years of age or more who has both severe mental retardation and severe Limb/Trunk Dysfunction, when a prefectural government finds that the welfare of the child is likely to be impaired unless he/she receives Designated Institutional Support pertaining to severely-retarded child institution, the prefectural government may, notwithstanding the provision of Article 24-2 paragraph (1), Article 24-6 paragraph (1), Article 24-7 paragraph (1) or Article 24-20 paragraph (1), continue to pay or provide to said person Institutional Benefits for Disabled Children, etc. pertaining to institutional support for severely-retarded children based on said person's application, pursuant to the provisions of Ordinance of the Ministry of Health, Labour and Welfare; provided, however, that this shall not apply to the case where he/she can receive the Treatment and Care Services or other support.
    ２　都道府県は、第二十四条の二第一項、第二十四条の六第一項、第二十四条の七第一項又は第二十四条の二十第一項の規定にかかわらず、当分の間、重度の知的障害及び重度の肢体不自由が重複している満十八歳以上の者について、重症心身障害児施設支援に係る指定施設支援を受けなければその福祉を損なうおそれがあると認めるときは、その者からの申請により、厚生労働省令で定めるところにより、重症心身障害児施設支援に係る障害児施設給付費等を支給することができる。ただし、その者が療養介護その他の支援を受けることができる場合は、この限りでない。 - 日本法令外国語訳データベースシステム
＜前へ 1 2 3 4 5 6

例文データの著作権について